Carla Greenbaum, MD, is director of the Diabetes Program and Center for Interventional Immunology at BRI and the director of the NIH-sponsored TrialNet Clinical Network Hub. After medical school at Brown University, she completed her endocrinology fellowship at the University of Washington. See a list of Dr. Greenbaum’s publications here.
A citizen science game explores how social choices and networks can influence how an illness moves through a population.
View this Issue
Learn how a next-generation platform accelerates biological research by enabling high-throughput, spatially resolved multiomics profiling.
In this webinar, Imogen Binnian will share how AI and gene synthesis technology can accelerate the discovery and validation of novel disease traits.
Real-time imaging enhances fluorescence activated cell sorting (FACS) to help scientists overcome the cost and burden of validation.
New innovations provide scientists with easy access to robust and accurate control samples for quality control applications.
Setting new standards for intelligent mass detection, sensitivity, and sustainability.
The Wellcome Sanger Institute, Helmholtz Munich, and Parse Biosciences have announced a landmark international collaboration to create a Cancer Plasticity Atlas.
Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology.
Discover how Alderley Analytical meet regulatory demands and high-throughput challenges—processing 10,000+ dirty samples with consistent performance of the Xevo TQ Absolute XR Mass Spectrometer.
